MANDOL
LOE ApproachingNDAINJECTIONINJECTABLEPriority Review
Approved
Sep 1978
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Priority Review
Drug data last refreshed 4d ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
MANDOL is an injectable small-molecule antibiotic approved in 1978 by Eli Lilly. The exact indications are not specified in available data, but the product is positioned as an injection-based therapeutic. As a legacy injectable, MANDOL likely serves established clinical niches in hospital or institutional settings.
LOE Approaching
Approaching loss of exclusivity with limited linked job opportunities signals minimal commercial investment and small brand team operations.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Zero linked job openings reflect the product's mature, LOE-approaching lifecycle—this is not a growth opportunity. Roles on MANDOL focus on compliance, cost management, and gradual commercialization wind-down rather than expansion or innovation.
Product ManagerSales Representative
Worked on MANDOL at Eli Lilly and Company? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.